Genetic Immunity

About Us

Genetic Immunity Inc., is a privately-held, U.S. biopharmaceutical company that has developed a proprietary Langerhans cell targeting delivery system which can induce long-lasting T cell immunity for therapeutic vaccinations against infectious diseases and cancer. Our proprietary system delivers a genetically targeted nanomedicine formulation that can simultaneously express 15 disease-specific antigens. All of our medicines are delivered topically using our CE-marked medical device, DermaPrep™. Today, the National Institutes of Health (NIH) is sponsoring a clinical trial in 72 HIV-positive adolescents. Genetic Immunity plans to start a Phase IIB study on 120 HIV-positive adults and a Phase II study on Hepatitis C/HIV co-infected patients the later part of 2012. For more information on the Company, our products and our trials, please visit us on the web at: www.geneticimmunity.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Genetic Immunity Clinical Trial Data Published in Plos One

Thu, May 17, 2012 16:00 CET

Genetic Immunity Clinical Trial Data Published in Plos OneDermaVir Immunization Boosted Long-lasting Memory T-cell Responses in Every PatientMcLean, VA and Budapest, Hungary, May 17, 2102 – Genetic Immunity Inc ., a privately-held, biopharmaceutical company developing Langerhans cell-targeted immunotherapies, published its human proof-of-concept clinical trial, in PLoS ONE, a highly-regarded medical industry publication. The data demonstrated the induction of long-lasting memory T cell responses after a single immunization of DermaVir, the Company’s lead

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Genetic Immunity Clinical Trial Data Published in Plos One